NCT01709396View on ClinicalTrials.gov

ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS

PHASE2SuspendedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2018

Conditions
Acute LeukemiaMyelodysplastic Syndrome
Interventions
RADIATION

ED-TBI

Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.

Trial Locations (1)

K1H8L6

The Ottawa Hospital - General Campus, Ottawa

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER